Navigation Links
Pluromed, Inc. Signs Agreement with Boston Scientific
Date:10/8/2009

Boston Scientific to distribute Pluromed's BackStop™ device, a rapid phase transition gel used in the treatment of Kidney Stones.

Woburn, Massachusetts (PRWEB) October 9, 2009 -- Pluromed, Inc. has announced that it has entered into an alliance with Boston Scientific Corporation (NYSE: BSX) regarding Pluromed's BackStop™ product, a device used in ureteroscopic kidney stone management procedures. Boston Scientific has acquired the worldwide distribution rights to BackStop. The financial terms of the agreement were not disclosed.

Kidney stone disease is estimated to affect millions of people worldwide. A common method of treating these stones is intracorporeal lithotripsy where the stones are fragmented using a laser or other energy modality in a minimally invasive procedure. Backstop™ is based on Pluromed's proprietary Rapid Transition Polymers™ (RTP™) that are liquid at low temperature and transition to a gel at body temperature; the transition is reversible via cooling and the gel is completely dissolvable. The BackStop gel forms a plug above the stones in the ureter and is designed to prevent stone migration during the procedure. After stone fragmentation is complete, the gel is dissolved with saline and exits the body. The BackStop product offers the potential to reduce operating time and complexity, and improve "stone free" rates for patients.

"We are very pleased to work with with Boston Scientific," said John Merhige, Pluromed's Vice President of Market Development. "BSC is the market leader with the resources and expertise to get the BackStop product into the hands of urologists." The BackStop device is approved for sale in Europe, Canada and the United States.

Jean-Marie Vogel, Pluromed's CEO, said, "This alliance represents an important event in the evolution of Pluromed. The proceeds from the agreement allow us to further invest in growing our core cardiovascular business, and with Boston Scientific distributing the BackStop product, we anticipate a successful launch and ongoing growth."

Pluromed and Boston Scientific will be working closely on integrating the BackStop product into BSC's systems in anticipation of the worldwide product launch.


About Pluromed, Inc.
Pluromed, Inc., Woburn, Massachusetts, founded in 2003, is pioneering the use of atraumatic gel plugs to improve the safety, efficacy and economics of medical interventions. These products address a broad surgery market that includes cardiac and vascular surgery, prostate, kidney and liver surgery, plastic/reconstructive surgery, trauma/battlefield applications and the treatment of kidney stones. They are based on the Company's patented rapid phase transition polymer technology; Pluromed Rapid Transition Polymers™ (RTP™) are liquid at low temperature and quickly transition to a high viscosity gel at body temperature. For more information, please visit www.pluromed.com

About Boston Scientific Corporation
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com

###

Read the full story at http://www.prweb.com/releases/2009/10/prweb3011074.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. SEO Consultant Top Rank Web Designs Gives Away 250 Free Websites
2. /R E P E A T -- DiagnoCure signs distribution agreement in the UK for its colorectal cancer test/
3. DiagnoCure signs distribution agreement in the UK for its colorectal cancer test
4. AdaptaVan, LLC Signs Two New Dealers: Company's Wheelchair Accessible Vans Now Available in North Carolina and Missouri
5. The MED Group Signs Preferred Supplier Agreement for Masimo SET(R) Pulse Oximetry Solutions
6. Rapid Fire Marketing Signs 5 Year Agreement
7. Osseon Signs International Distribution Agreement With MBA Incorporado
8. New device finds early signs of eye disease in preemies
9. GENova Biotherapeutics signs LOI with Korean university for stem cell research and patents sharing
10. GENova Biotherapeutics signs engagement agreement with PacificWave Partners Limited
11. Haemonetics Signs Comprehensive Agreement with Blood Centers of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: